Darunavir in the treatment of HIV-1 infection: a viewpoint by Mark Holodniy.
Holodniy
Mark
M
AIDS Research Center, Department of Medicine, Stanford University, Palo Alto, California, USA.
D002986:Clinical Trials as Topic; D000069454:Darunavir; D024882:Drug Resistance, Viral / Q000235:genetics; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load
D017320:HIV Protease Inhibitors; D013449:Sulfonamides; D000069454:Darunavir